Clinical trials
Epithelial Ovarian Cancer clinical trials
Below are recruiting epithelial ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 235 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05172310RecruitingPhase 1
PET scan study using a new tracer for solid tumors
This trial tests a special PET/CT scan using a new tracer (68Ga-FAPI) to help show tumors in the pancreas, bile ducts, stomach, or certain ovarian cancers. It may help doctors better see where cancer is in preparation for surgery or biopsy.
StockholmAges 19 years+ - NCT06341907RecruitingPhase 2/Phase 3
Vaccine and blood test to prevent ovarian cancer return
This trial tests a personalized vaccine for people with epithelial ovarian cancer who still have a small amount of cancer DNA in their blood after surgery. The goal is to see if the vaccine can help stop the cancer from coming back.
Wenzhou, ZhejiangAges 18–70 - NCT06378905Recruiting
Testing a new score for advanced ovarian cancer
This study is testing a new scoring system (Cukurova Score) to help doctors better understand and treat advanced ovarian, fallopian tube, or peritoneal cancer. By joining, you could help improve how we predict outcomes for people with these cancers.
AdanaAges 18–100 - NCT06873555RecruitingPhase 1/Phase 2
Study of a new drug for ovarian cancer and other advanced solid tumors
This trial tests a new drug (DC05F01) for people with ovarian cancer that has come back after platinum treatment, or for those with other advanced solid tumors that haven't responded to standard therapies. It aims to see if the drug is safe and effective.
Bengbu, AnhuiAges 18 years+ - NCT06906341RecruitingPhase 2
Relacorilant combo for gynecologic cancers
This trial tests a drug called relacorilant combined with different treatments for ovarian, fallopian tube, primary peritoneal, or endometrial cancers. It may help patients whose cancer has stopped responding to standard therapies.
Birmingham, AlabamaAges 18 years+ - NCT07214779RecruitingPhase 3
New drug vs chemo for platinum-resistant ovarian cancer
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Anchorage, AlaskaAges 18 years+ - NCT05027828Recruiting
Blood test may track ovarian cancer treatment response
This study checks whether a blood test (ctDNA) can show how well ovarian, fallopian tube, or primary peritoneal cancer treatment is working. If the test reliably reflects response, it could help doctors adjust treatment earlier and more precisely.
ShanghaiAges 18 years+ - NCT07023627RecruitingPhase 2
New pill for platinum-resistant ovarian cancer with cyclin E1
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
Mobile, AlabamaAges 18–99 - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT07024784RecruitingPhase 2
Study of IMGN151 for gynecologic cancers
This study tests a new drug (IMGN151) given intravenously, alone or with other therapies, for people with certain gynecologic cancers, specifically high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and what side effects might occur.
Teaneck, New JerseyAges 18 years+ - NCT06083844RecruitingPhase 2
Keytruda + Avastin + chemo for ovarian cancer with minimal remaining disease
This trial tests a combination of three drugs—pembrolizumab (Keytruda, an immunotherapy), bevacizumab (Avastin, a blood-vessel blocker), and oral cyclophosphamide (a chemotherapy pill)—for women with high-grade ovarian cancer who have only tiny bits of disease left after finishing their initial treatment.
New York, New YorkAges 18 years+ - NCT06817174Recruiting
CT scan analysis for ovarian cancer treatment planning
This study uses advanced computer analysis of CT scans to help doctors plan the best treatment for advanced ovarian cancer. It is designed for patients who are about to start active treatment, such as surgery or chemotherapy.
LondonAges 18 years+ - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+ - NCT05704621RecruitingPhase 2
Surgery after PARP inhibitor failure in returning ovarian cancer
This trial tests whether doing additional (“secondary”) tumor-removal surgery can help people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after PARP inhibitor maintenance. It focuses on people whose cancer can likely be fully removed and who are considered good candidates for surgery and follow-up treatment.
SeoulAges 18 years+ - NCT06533709Recruiting
Can PET-CT predict ovarian cancer surgery success?
This trial uses PET-CT scans to create a model that predicts how completely advanced ovarian cancer can be removed during surgery. It may help doctors plan the best treatment for you.
Guangzhou, GuangdongAges 18–80 - NCT07572409Recruiting
Lymph Node Surgery for Advanced Ovarian Cancer
This study tests whether removing enlarged lymph nodes near the heart and lungs during surgery for advanced ovarian cancer can help you live longer and feel better. You must have already had surgery to remove most of your tumor and have specific lymph node changes on imaging.
Changchun, JilinAges 18–70 - NCT07489287RecruitingPhase 1
GB-5267 for platinum-resistant ovarian, peritoneal, or fallopian tube cancer
This trial tests a new cell therapy (GB-5267) for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. It requires multiple tumor biopsies and aims to see if the treatment can help when standard chemo stops working.
Buffalo, New YorkAges 18 years+ - NCT06365853RecruitingPhase 2
Study of eye safety during treatment with MIRV for recurrent ovarian cancer
This trial tests a targeted drug called mirvetuximab soravtansine (MIRV) for recurrent ovarian cancer that has high levels of a protein called FRα. The study focuses on monitoring and preventing eye-related side effects, which are common with this treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT07495384Recruiting
CapsuleX and cisplatin for platinum-resistant ovarian cancer
This study tests a new treatment combination (CapsuleX plus cisplatin) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help when the cancer has progressed within 6 months of last platinum treatment.
Changchun, JilinAges 18 years+ - NCT05231122RecruitingPhase 2
Pembrolizumab and bevacizumab for recurrent ovarian cancer
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Buffalo, New YorkAges 18 years+ - NCT07407062Recruiting
Study of folate receptor alpha in ovarian cancer tissue
This study looks at a marker called folate receptor alpha in tissue samples from people with ovarian, fallopian tube, or primary peritoneal cancer that has returned. The goal is to see how common this marker is, which may help guide future treatment options.
Rome, RomaAges 18 years+ - NCT06588322Recruiting
Detecting gene changes in blood of ovarian cancer patients on PARP inhibitor
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
AngersAges 18 years+ - NCT04633239RecruitingPhase 1
Testing abemaciclib plus olaparib for recurrent ovarian cancer
This Phase 1 trial studies whether adding abemaciclib to olaparib can treat women with recurrent platinum-resistant ovarian cancer. It aims to find a safe dose and see how well the combination can control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT04590326RecruitingPhase 1/Phase 2
Study of REGN5668 with or without immunotherapy in ovarian cancer
This Phase 1/2 study tests how safe REGN5668 is and how well it works in adult women with advanced gynecologic cancers. It compares REGN5668 given with cemiplimab alone, or cemiplimab plus fianlimab, and looks for responses in tumors that meet specific criteria.
Duarte, CaliforniaAges 18 years+
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for epithelial ovarian cancer?
- Yes. Clin2 currently lists 235 recruiting epithelial ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a epithelial ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a epithelial ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.